co stryker corp
kstew updat call tidbit read-thru
 ant pass along tidbit earn call today quest cover meehan geting cover
roch cover emmanuel papadaki relev coverag univers ant highlight tw particular
read-thru one hich get frequent question
equal weight stock rel outperform sinc end februari share
versu dow hc equip suppli quest result show lab volum
reduc compani expect volum remain depress second quarter sell product lab compani
blood collect tube needl preanalyt solut busi hich repres sale busi
like also see low er sale lab compani hospit physician offic order less suppli get
question bd exposur test bd diagnost busi sale could see benefit higher
sale assay bd system ell nasal sw ab viral collect tube bd also announc partnership
 hich sell serolog test ell hich help forw ard ever expect offset similar
 hat diagnost compani seen exampl low er sale omen health std test result er
offic visit bd exposur elect procedur volum intervent busi unit sale moreov bd
could also impact low er hospit censu low er physician offic visit hich could impact medic deliveri solut
sale abil sell alari pump medic necess good thing sale ere guidanc
constrain hospit capital-expenditure environ go forw ard gener good er oil price may translat time
reduc resin price low er cog that good stronger us dollar like eigh sale profit good
net/net put take across portfolio hile may neg impact
med-tech space immun maintain equal eight rate
underweight medtron last night geting today indic hospit pull back capit
expenditur relat also continu concern pace recoveri ith elect procedur
particularli qualiti life natur major joint replac increas discuss
around orri potenti second ave fall/w inter state open
cover meehan us lifesci tool diagnost
morn releas result quest previous comment quarter via file march note
last tw eek march saw volum declin excess inclus test ow ing cancel
elect procedur declin physician offic
today call quest provid addit color believ provid help read-thru med-tech space
particularli hich sell preanalyt product blood collect tube needl etc lab compani like quest
also relev lab player like abbott lab hich sell equip moreov give sens util healthcar
broadli
call quest note
late march commentari last tw eek quarter volum declin excess across
metropolitan market hotspot like new york citi
april thu far quest note volum declin continu intensifi volum declin ere bottom around dow
 hich includ benefit molecular test hich run approxim test per day
averag approxim volum grow th
expect ahead quest expect volum ithout test dow second quarter
stay-at-hom measur begin lift quest believ volum improv low er level start year
kstew read-thru er lab test volum like impact bd preanalyt busi
sale bd suppli blood collect tube ell needl product relat abbott
compani alreadi discuss impact low er diagnost test lab busi sale
believ trend ell understood market
quest also note care act suspend pama price cut ere schedul
kstew read-thru could help eas financi strain lab hich view posit
geting getib ss cover
morn geting releas result remind geting global healthcar compani headquart sw eden
sell product intens care cardiovascular procedur oper room steril reprocess life scienc
geting coverag barclay research inform compani provid inform purpos
invest recommend barclay research
geting note signific increas order
geting note order ere strongest acut care therapi note order advanc ventil icu
estim market share increas capac icu ventil ventil also note
signific increas demand extracorpor membran oxygen machin ecmo estim market share
gradual ramp product capac
kstew read-thru also note see higher demand ventil ell ecmo
product note kstew updat medtron first look bad number may look like
convers geting note declin order surgic workplaces/oper room equip ell life scienc
manag note increas rate end quarter
kstew read-thru geting estim leader surgic orkplac ith market share
also sell /surgic orkplac equip hospit capit equip includ ithin stryker
endoscopi busi hich repres sale also capit equip outsid bed
busi medic instrument franchis ell moreov mako robot could also someth see
push-out instal offer financ leas option nevertheless trend seen ith geting lead
us reaffirm underweight note hillrom also part busi cater outfit
surgic room ever believ enough offset thu maintain overw eight rate
roch sw cover emmanuel papadaki eu
updat testingad antibodi test month
 first compani ith test receiv ce fda emerg use author march high throughput
coba system
number instruments/system market coba system place
current assay/test manufactur capac test per month
roch also note offer tib molbiol lightmix modular ce approv assay primer probe screen confirm
research use also provid system magna purs lightcycl instrument reagent
roch announc plan launch antibodi test elecsi assay earli may test ill
run global coba instal base system ith throughput test per
plan ramp high doubl digit million test per month june indic ill scale beyond
fast possibl
specif sensit manag note still final believ specif
import number thought go reliabl test plan commun later date
manag said test valid test ant commun number final
note precis number ill come hen assay launch
respons question serolog test immun manag respond ould agre ith ho test
taken venou ould better finger prick ould agre need better understand immun long
kstew read-thru overal roch leader diagnost test space result continu show
impact low er elect procedur ell higher sale relat test
remind check deep dive examin near potenti long-term rippl effect
alway stay safe stay healthi well kind feel free reach
click titl access note
believ great read deep dive examin near potenti long-term rippl effect think
investor visual novel coronaviru giant boulder throw lake creat big initi
splash upon entri rippl ill seen felt reach far shore time initi focu
investor commun big splash creat near-term effect import question difficult
answ er hat effect rippl hat long-term impact healthcar industri
 holeprovid physician patient insur cours med-tech compani report aim
 healthcar physician survey reduc offic visit procedur across multipl specialti barclay
global healthcar survey physician state across differ sub-specialti includ intervent
endocrinolog dermatolog neurolog hemo-oncolog rheumatolog evalu impact practic trend
particularli offic volum elect procedur prescript pattern nearli physician report signific declin
patient offic visit averag visit around primari reason behind declin appear
patient cancel visit telehealth appoint significantli perhap enough off-set declin in-person
visit major physician indic facil hospit asc offices/surgi-cent implement
polici cancel elect procedur led signific reduct surgeri report list common
elect procedur specialti cancel usual suspect like knee hip replac arthroscopi radiofrequ
ablat nerv block spinal fusion stent etc ere list think list greater might think
includ procedur like valv replac tavr laa prevent icd pacemak cabg peripher intervent
endoscopi prostatectomi db also talk implic med-tech
 medic suppli devic put take isrg-get readi arn flag insid
reportw review med-tech takeaw ay barclay global healthcar confer discuss american colleg
surgeon surgeon gener recommend cancel elect procedur review state health system
hospit taken action limit elect procedur action relev medic devic includ
commentari regard build new bed review hat elect procedur discuss product mix compani
 review hat product could use effort compani manufactur product
 kstew updat first look bad number may look like even
provid updat result hich end april net/net impact signific neg
despit even product line like ventil patient monitor devic higher demand ith
 believ new like eigh stock short term other med-tech sector
kstew updat call tidbit read-thru med-tech cover steve
valiquett releas result morn ant pass along comment made
earn call morn provid read-through medic devic suppli univers highlight tw
name particular-conm cnmd-overw eight syk-underw eight
kstew updat philip read-thru med-tech maintain ow uw philip phia na cover
hassan al-w akeel eu med-tech servic analyst report result philip provid read-thru coverag
univers particularli compani ith hospit capital-expenditure commentari lead us reaffirm overw eight rate hillrom
hrc-report result may underw eight rate report result april
kstew updat hen open or ill come look open america open
america guidelin includ framew ork around restart elect procedur phased-in approach view
still lot open question decis hand individu state hen restart hen
allow elect procedur still yet individu hospit implement restart
kstew updat baxter updat read-thru serolog test vent contract updat ant
highlight coupl updat tonight baxter see increas demand across certain product serolog test
updat landscap vent contracts- provid updat contract hillrom contract price million
 view amount hillrom posit give us addit confid outlook thesi
kstew updat urgent deferr thought procedur edit review
procedur -- commentari provid manag journal articl stemi heart attack procedur state elect
order elect procedur
kstew updat count eather cdc outlin return ork guidelin present
find nation academi scienc engin medicin committe find relat
temperatur humid potenti season
kstew updat ny apex vent updat abt dx airtim presid trump other
updat discuss updat ny state trend updat hite hous press brief
ventil ell abbott test
hill-rom hold inc upgrad overw eight readi abl assist ith estim least
hillrom sale rental bed legaci elch allyn product thermometri patient monitor blood pressur
physic examin product could use help triag assess monitor aid treatment patient hillrom
also recent acquir hich non-invas ventil anoth hillrom busi
acut care frame hich includ icu bed mani hospit state cite shortag
kstew updat aim doubl capac global demand reiter ow reiter
overw eight rate hillrom market close hillrom announc global demand sever critic product
grow substanti ork significantli ramp product ith goal doubl capac
follow ing area respiratori health icu med-surg smart bed patient monitor diagnost
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
co usd equal eight/neutr a/cd/ce/d/e/j/k/l/m/n
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog price target
appli multipl calendar ep
risk may imped achiev barclay research valuat price upsid risk factor
extent becton success integr bard see greater expect revenue/cost synergi shorter time period
resolv alari pump issu greater success ith new product nside fx stronger us dollar commod cost
could greater headw ind risk factor includ time success new product delay resolv alari pump
issu increas competit key product drug-coat balloon infus pump signific chang reimburs
fda govern action
rate price target histori
co
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog price target
appli pe multipl ep estim expect multipl compress ow ing elect procedur
capital-expenditure exposur underli sale grow th slow
risk may imped achiev barclay research valuat price fx rate recent acquisit
could pressur earn grow th competit pressur particularli area knee competitor launch compet
robotic-assist system could impact grow th outlook sentiment tow ard stock time ultim receipt new
product approv could affect outlook risk includ integr right acquisit signific chang
reimburs potenti dilut associ ith acquisit product failur fda govern action
deterior cash flow could also risk factor
rate price target histori
prior intra-day chang may publish rate secur underw eight
adjust price target
histor stock price price target may adjust stock split dividend
unless otherw ise indic price sourc bloomberg reflect close price relev trade market hich
may last avail price time public
